Loading clinical trials...

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

Randomized, Comparative, Double-blind, Placebo-controlled, Triple-dummy, Four-way Cross-over Study to Investigate Neurocognitive Effects of Brivaracetam in Healthy Subjects

NCT00736931•UCB Pharma

View on ClinicalTrials.gov

Summary

The primary objective of the study is to evaluate the neurocognitive effects of brivaracetam

Eligibility

Age

18 - 50 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy male or female volunteer aged 18 to 50 years inclusive
•Body Mass Index (BMI) between 18.0 and 30.0 kg/m² inclusive
•Good physical and mental health status
•Blood pressure and heart rate within normal range
•Electrocardiogram and laboratory tests without clinically significant abnormality

Exclusion Criteria

•IQ ≤ 80 as determined by Test of non-verbal intelligence
•Center for Epidemiological Studies Depression (CES-D Scale ≥16,
•Known allergy/intolerance to pyrrolidinone derivatives
•Abnormalities on EEG recordings
•Pregnant, lactating women
•History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, neurological, psychiatric disorders
•Use of any hepatic enzyme-inducing drug

Locations (1)

Overland Park, Kansas, United States

Key Dates

Start Date

July 1, 2008

Primary Completion Date

October 1, 2008

Completion Date

October 1, 2008

Last Updated

May 28, 2012

Enrollment

ACTUAL participants

Conditions

Epilepsy

Interventions

Brivaracetam

DRUG

levetiracetam

DRUG

lorazepam

DRUG

placebo

OTHER

Thalamus Seizure Detection With a Deep Brain Stimulator System

NCT06700356

Epilepsy; Seizure

View study

RECRUITINGPHASE1

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880

Epilepsy

View study

RECRUITINGNA

Intracranial Investigation of Neural Circuity Underlying Human Mood

NCT05871372

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 28, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

Inclusion Criteria

Exclusion Criteria

Thalamus Seizure Detection With a Deep Brain Stimulator System

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Intracranial Investigation of Neural Circuity Underlying Human Mood

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Late-Onset Seizures: Trial of Vascular Risk Investigation and Treatment

MEHMO Natural History and Biomarkers